FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2552672983> ?p ?o ?g. }

• W2552672983 abstract "Abstract Background: The nuclear factor kappa B (NFkB) signaling pathway is constitutively activated and central to the pathogenesis of multiple myeloma (MM). We previously published the antitumor activity of the NFkB inhibitor parthenolide in MM. Dimethylaminoparthenolide (DMAPT) is a water-soluble analog of parthenolide. The improved bioavailability of DMAPT makes its appealing for clinical development. Objectives: To validate the effects of DMAPT both in vitro and in vivo MM models and to develop a rational strategy for a combination of DMAPT with other anti-MM agents. Methods: The in vitro cytotoxicity of DMAPT was tested in human MM cell lines and primary samples both alone and in combination with bortezomib and lenalidomide. The in vivo activity of DMAPT was tested in a model of NOD/Scid mice intravenously transplanted with GFP-tagged NCI-H929 MM cells. Results: Based on MTT assays on MM cell lines and primary MM cells, the IC50 for proliferation inhibition of DMAPT was similar to that of parthenolide (1–3 μM). When used in combination with bortezomib, we observed synergy (combinatorial index < 1.0) at higher doses of DMPT and bortezomib (DMAPT 2.5–5 μM and bortezomib 5–12.5 nM), while an antagonistic effect was observed at lower doses. Similarly, when combined with lenalidomide, synergy was observed at DMAPT doses 1.6–6.4 μM and lenalidomide doses 0.5–2 μM, while an antagonistic effect was observed at lower doses. The in vivo cytotoxicity of DMAPT was explored in a model of NOD/Scid mice intravenously transplanted with GFP-tagged NCI-H929 cells. At 3 weeks post-transplantation, all animals had measurable serum human kappa light chain levels, as measured by ELISA assays. Animals were randomized to receive either 50 mg/kg/day DMAPT (n=12), 100 mg/kg/day DMAPT (n=12) or vehicle (n=10) via oral gavage for a duration of 6 weeks or until criteria for euthanasia were met. Weight loss of over 15% and hind leg paralysis were criteria for euthanasia. Toxicities in both treatment groups were minimal. Weight loss correlated with serum human kappa light chain levels and, hence, represented disease progression. At the end of treatment, there were 2 animals alive in the control group, while 5 were alive in each of the treated groups. Using Kaplan-Meier curves and log-rank analysis, the mean overall survival (OS) was 56.3 days in the control cohort versus 61.0 days and 62.4 days in groups treated with 50 and 100 mg/kg/day DMAPT, respectively. There was no statistically significant difference in the mean OS of mice treated with the two doses of DMAPT (p=0.07). Prior to treatment initiation, the serum levels of human kappa light chains were similar in all groups (ANOVA test, p= 0.38). At 2 weeks and 4 weeks post treatment (Week 5 and week 7, respectively; See table), the levels of human kappa light chains were significantly lower in the DMAPT treated groups (ANOVA test p = 0.017 and 0.0061, respectively). Week 3 Week 5 Week 7 Control 10.46 ± 5.79 531.31 ± 238 6272.1 ± 3211 DMAPT 50 mg/kg/day 6.94 ± 4.48 264.03 ± 198 2928.8 ± 2131 DMAPT 100 mg/kg/day 7.99 ± 7.21 334.15 ± 198 3374.9 ± 1835 ANOVA (P value) 0.38 0.017 0.0061 Conclusions: DMAPT demonstrated excellent efficacy in preclinical models of MM and supports a rationale for its clinical development in MM patients with relapsed MM either alone or in combination with bortezomib or lenalidomide." @default.
• W2552672983 created "2016-11-30" @default.
• W2552672983 creator A5047486042 @default.
• W2552672983 creator A5052787074 @default.
• W2552672983 creator A5056623541 @default.
• W2552672983 creator A5056697792 @default.
• W2552672983 creator A5073818711 @default.
• W2552672983 creator A5074556426 @default.
• W2552672983 creator A5083049265 @default.
• W2552672983 creator A5089265440 @default.
• W2552672983 date "2008-11-16" @default.
• W2552672983 modified "2023-10-01" @default.
• W2552672983 title "Dimethylaminoparthenolide (DMAPT) in Multiple Myeloma" @default.
• W2552672983 doi "https://doi.org/10.1182/blood.v112.11.3672.3672" @default.
• W2552672983 hasPublicationYear "2008" @default.
• W2552672983 type Work @default.
• W2552672983 sameAs 2552672983 @default.
• W2552672983 citedByCount "0" @default.
• W2552672983 crossrefType "journal-article" @default.
• W2552672983 hasAuthorship W2552672983A5047486042 @default.
• W2552672983 hasAuthorship W2552672983A5052787074 @default.
• W2552672983 hasAuthorship W2552672983A5056623541 @default.
• W2552672983 hasAuthorship W2552672983A5056697792 @default.
• W2552672983 hasAuthorship W2552672983A5073818711 @default.
• W2552672983 hasAuthorship W2552672983A5074556426 @default.
• W2552672983 hasAuthorship W2552672983A5083049265 @default.
• W2552672983 hasAuthorship W2552672983A5089265440 @default.
• W2552672983 hasConcept C109316439 @default.
• W2552672983 hasConcept C126322002 @default.
• W2552672983 hasConcept C150903083 @default.
• W2552672983 hasConcept C185592680 @default.
• W2552672983 hasConcept C190283241 @default.
• W2552672983 hasConcept C202751555 @default.
• W2552672983 hasConcept C203014093 @default.
• W2552672983 hasConcept C207001950 @default.
• W2552672983 hasConcept C26291073 @default.
• W2552672983 hasConcept C2776063141 @default.
• W2552672983 hasConcept C2776364478 @default.
• W2552672983 hasConcept C2777478702 @default.
• W2552672983 hasConcept C2780321935 @default.
• W2552672983 hasConcept C2780783641 @default.
• W2552672983 hasConcept C2911091166 @default.
• W2552672983 hasConcept C502942594 @default.
• W2552672983 hasConcept C55493867 @default.
• W2552672983 hasConcept C71924100 @default.
• W2552672983 hasConcept C86803240 @default.
• W2552672983 hasConcept C98274493 @default.
• W2552672983 hasConceptScore W2552672983C109316439 @default.
• W2552672983 hasConceptScore W2552672983C126322002 @default.
• W2552672983 hasConceptScore W2552672983C150903083 @default.
• W2552672983 hasConceptScore W2552672983C185592680 @default.
• W2552672983 hasConceptScore W2552672983C190283241 @default.
• W2552672983 hasConceptScore W2552672983C202751555 @default.
• W2552672983 hasConceptScore W2552672983C203014093 @default.
• W2552672983 hasConceptScore W2552672983C207001950 @default.
• W2552672983 hasConceptScore W2552672983C26291073 @default.
• W2552672983 hasConceptScore W2552672983C2776063141 @default.
• W2552672983 hasConceptScore W2552672983C2776364478 @default.
• W2552672983 hasConceptScore W2552672983C2777478702 @default.
• W2552672983 hasConceptScore W2552672983C2780321935 @default.
• W2552672983 hasConceptScore W2552672983C2780783641 @default.
• W2552672983 hasConceptScore W2552672983C2911091166 @default.
• W2552672983 hasConceptScore W2552672983C502942594 @default.
• W2552672983 hasConceptScore W2552672983C55493867 @default.
• W2552672983 hasConceptScore W2552672983C71924100 @default.
• W2552672983 hasConceptScore W2552672983C86803240 @default.
• W2552672983 hasConceptScore W2552672983C98274493 @default.
• W2552672983 hasLocation W25526729831 @default.
• W2552672983 hasOpenAccess W2552672983 @default.
• W2552672983 hasPrimaryLocation W25526729831 @default.
• W2552672983 hasRelatedWork W1443108546 @default.
• W2552672983 hasRelatedWork W2108686552 @default.
• W2552672983 hasRelatedWork W2125209398 @default.
• W2552672983 hasRelatedWork W2184894809 @default.
• W2552672983 hasRelatedWork W2369764254 @default.
• W2552672983 hasRelatedWork W2376976586 @default.
• W2552672983 hasRelatedWork W2378628095 @default.
• W2552672983 hasRelatedWork W2388762021 @default.
• W2552672983 hasRelatedWork W2550365187 @default.
• W2552672983 hasRelatedWork W2557733183 @default.
• W2552672983 hasRelatedWork W2558296050 @default.
• W2552672983 hasRelatedWork W2559882666 @default.
• W2552672983 hasRelatedWork W2564031135 @default.
• W2552672983 hasRelatedWork W2572796572 @default.
• W2552672983 hasRelatedWork W2588538618 @default.
• W2552672983 hasRelatedWork W2588974447 @default.
• W2552672983 hasRelatedWork W2784043644 @default.
• W2552672983 hasRelatedWork W2978553166 @default.
• W2552672983 hasRelatedWork W3030508989 @default.
• W2552672983 hasRelatedWork W3211138513 @default.
• W2552672983 isParatext "false" @default.
• W2552672983 isRetracted "false" @default.
• W2552672983 magId "2552672983" @default.
• W2552672983 workType "article" @default.